NCT02184962

Brief Summary

The aim of this study was to investigate the levels of RANKL and Osteoprotegerin, and their relationship in gingival crevicular fluid of post-menopausal women with osteoporosis/osteopenia and chronic periodontitis simultaneously and evaluate the effect that the use of bisphosphonates in periodontal disease. Study hypothesis: "The osteoporosis / osteopenia in postmenopausal women patients with periodontal disease affect the ratio RANKL / OPG in gingival crevicular fluid samples favoring osteoclastogenesis processes "

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
81

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

July 3, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 9, 2014

Completed
Last Updated

July 9, 2014

Status Verified

July 1, 2014

Enrollment Period

1.3 years

First QC Date

July 3, 2014

Last Update Submit

July 8, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • levels of RANKL and OPG

    one year

Eligibility Criteria

Age45 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with osteopenia / osteoporosis and controls with normal osseous condition. Both groups with chronic periodontitis

You may qualify if:

  • Women between 45-70 years with Absorptiometry Dual Energy X-ray (DEXA).
  • Control group: post-menopausal women with periodontal disease and normal osseous condition.
  • Study group: post-menopausal womens with periodontal disease and osteoporosis/osteopenia with and without bisphosphonate treatment (risedronate or ibandronate 150 mg) for longer than 3 months before the study and another.

You may not qualify if:

  • Patients with history of aggressive periodontitis and had received any periodontal treatment when they entered the study
  • Patients with any systemic illness (except osteopenia/osteoporosis)
  • Patients who received antibiotic or non-steroidal anti-inflammatory therapy in the 6 months prior to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Facultad de Odontología - Universidad Nacional de Córdoba

Córdoba, Córdoba Province, 5000, Argentina

Location

MeSH Terms

Conditions

OsteoporosisBone Diseases, MetabolicPeriodontal Diseases

Condition Hierarchy (Ancestors)

Bone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • María E Verde, Odontóloga

    Facultad de Odontología - UNC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
María Eugenia Verde - Cátedra de Periodoncia A - UNC

Study Record Dates

First Submitted

July 3, 2014

First Posted

July 9, 2014

Study Start

May 1, 2012

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

July 9, 2014

Record last verified: 2014-07

Locations